Characteristics of B-CLL patients treated with nonmyeloablative peripheral blood alloHSCT
| Patient . | A . | B . |
|---|---|---|
| Indication | Relapse | Relapse |
| Sex | Male | Female |
| Age* | 52 | 48 |
| Enrollment | 2003 | 2002 |
| Clinical trial† | NCT00055744 | NCT00003838 |
| Induction chemotherapy | EPOCH + FR | FC |
| Donor‡ | Brother | Brother |
| GVHD prophylaxis | CSP + MTX | CSP + MTX |
| Acute GVHD | No | No |
| Chronic GVHD | No | No |
| Response | PR; CR after DLI | CR |
| Current status§ | Molecular remission | Molecular remission |
| Patient . | A . | B . |
|---|---|---|
| Indication | Relapse | Relapse |
| Sex | Male | Female |
| Age* | 52 | 48 |
| Enrollment | 2003 | 2002 |
| Clinical trial† | NCT00055744 | NCT00003838 |
| Induction chemotherapy | EPOCH + FR | FC |
| Donor‡ | Brother | Brother |
| GVHD prophylaxis | CSP + MTX | CSP + MTX |
| Acute GVHD | No | No |
| Chronic GVHD | No | No |
| Response | PR; CR after DLI | CR |
| Current status§ | Molecular remission | Molecular remission |
EPOCH + FR indicates etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin plus fludarabine, rituximab; FC indicates fludarabine, cyclophosphamide; CSP + MTX, cyclosporine plus methotrexate; PR, partial response; CR, complete response; and DLI, donor lymphocyte infusion
At enrollment.
ClinicalTrials.gov identifier.
HLA-matched (6/6; A, B, and DR).
May 2009.